Historical Valuation
Lineage Cell Therapeutics Inc (LCTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.61 is considered Undervalued compared with the five-year average of -9.84. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 254.25 to 255.13 according to relative valuation methord. Compared to the current price of 1.71 USD , Lineage Cell Therapeutics Inc is Undervalued By 99.33%.
Relative Value
Fair Zone
254.25-255.13
Current Price：1.71
99.33%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lineage Cell Therapeutics Inc (LCTX) has a current Price-to-Book (P/B) ratio of 17.14. Compared to its 3-year average P/B ratio of 4.29 , the current P/B ratio is approximately 299.93% higher. Relative to its 5-year average P/B ratio of 3.83, the current P/B ratio is about 347.95% higher. Lineage Cell Therapeutics Inc (LCTX) has a Forward Free Cash Flow (FCF) yield of approximately -5.25%. Compared to its 3-year average FCF yield of -12.45%, the current FCF yield is approximately -57.82% lower. Relative to its 5-year average FCF yield of -8.69% , the current FCF yield is about -39.57% lower.
P/B
Median3y
4.29
Median5y
3.83
FCF Yield
Median3y
-12.45
Median5y
-8.69
Competitors Valuation Multiple
AI Analysis for LCTX
The average P/S ratio for LCTX competitors is 19754.65, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX.A) exhibits a P/S ratio of 30.61, which is -99.85% above the industry average. Given its robust revenue growth of -2.59%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LCTX
1Y
3Y
5Y
Market capitalization of LCTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LCTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LCTX currently overvalued or undervalued?
Lineage Cell Therapeutics Inc (LCTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 30.61 is considered Undervalued compared with the five-year average of -9.84. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 254.25 to 255.13 according to relative valuation methord. Compared to the current price of 1.71 USD , Lineage Cell Therapeutics Inc is Undervalued By 99.33% .
What is Lineage Cell Therapeutics Inc (LCTX) fair value?
LCTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lineage Cell Therapeutics Inc (LCTX) is between 254.25 to 255.13 according to relative valuation methord.
How does LCTX's valuation metrics compare to the industry average?
The average P/S ratio for LCTX's competitors is 19754.65, providing a benchmark for relative valuation. Lineage Cell Therapeutics Inc Corp (LCTX) exhibits a P/S ratio of 30.61, which is -99.85% above the industry average. Given its robust revenue growth of -2.59%, this premium appears unsustainable.
What is the current P/B ratio for Lineage Cell Therapeutics Inc (LCTX) as of Jan 10 2026?
As of Jan 10 2026, Lineage Cell Therapeutics Inc (LCTX) has a P/B ratio of 17.14. This indicates that the market values LCTX at 17.14 times its book value.
What is the current FCF Yield for Lineage Cell Therapeutics Inc (LCTX) as of Jan 10 2026?
As of Jan 10 2026, Lineage Cell Therapeutics Inc (LCTX) has a FCF Yield of -5.25%. This means that for every dollar of Lineage Cell Therapeutics Inc’s market capitalization, the company generates -5.25 cents in free cash flow.
What is the current Forward P/E ratio for Lineage Cell Therapeutics Inc (LCTX) as of Jan 10 2026?
As of Jan 10 2026, Lineage Cell Therapeutics Inc (LCTX) has a Forward P/E ratio of -16.22. This means the market is willing to pay $-16.22 for every dollar of Lineage Cell Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lineage Cell Therapeutics Inc (LCTX) as of Jan 10 2026?
As of Jan 10 2026, Lineage Cell Therapeutics Inc (LCTX) has a Forward P/S ratio of 30.61. This means the market is valuing LCTX at $30.61 for every dollar of expected revenue over the next 12 months.